EUCTR2006-003065-14-DE进行中（未招募）不适用
Investigation of a preseasonal rush treatment scheme with Depigoid® Grass Mix as an add-on therapy in patients with allergic rhinitis and/or rhinoconjunctivitis sensitized to grass pollen
ETI Pharma GmbH0 个研究点开始时间: 2006年11月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Prior to study specific examinations the patient has to give his/her written informed consent
- •2.Patients (= 12 years old) with a history of moderate to severe intermittent rhinitis and/or rhinoconjunctivitis during the grass season according to ARIA classification (28)
- •3.Symptoms more than 2 years prior to study start
- •4.Detectable specific IgE = 2 CAP RAST to grass pollen at the screening visit (V1) or within the previous 12 months
- •5.Positive skin-prick test (wheal diameter of at least 3 mm > negative control; Phleum pollen, 30 HEPL/ml; Laboratorios LETI, S.L, Tres Cantos, Spain)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Disease specific criteria
- •1.History of significant clinical manifestations of allergy as a result of sensitiza-tion against tree pollen allergens, weed allergens and perennial allergens (e.g. Aspergillus spores, animal dander, house dust mite)
- •For clarification:
- •According to the decision tree (see Appendix 3) patients with typical symptoms against the co-allergens birch, house dust mite, cat and dog are not allowed to en-ter the trial. Patients without symptoms will enter the trial if they are not exposed to the allergen even if CAP RAST is = 2. In case they are exposed to the allergen they must have a specific CAP RAST < 2 to be able to enter the trial.
- •2.Persistent asthma (GINA = II) according to ARIA classification (29)
- •3.Uncontrolled asthma, defined as FEV1 or PEF = 70% of predicted normal value
- •Patients with other known concomitant diseases / treatments
- •4.Active tuberculosis
- •5.Acute and chronic inflammatory or infectious diseases at the target organ effective
- •6.Advanced secondary changes at the target organ (e.g. emphysema or bronchiectasis)
- •7.Autoimmune disorders (e.g. of the liver, kidney, the nervous system, thyroid gland, rheumatic diseases)
- •8.Immune deficiencies
- •9.Any disease which prohibits the use of adrenaline (e.g. hyperthyroidism)
- •10.Cardiovascular insufficiency or any severe or unstable pulmonary, or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematologic disorder; any other clinically significant medical condition that could increase the risk to the study participant
- •11.History of malignancy of any organ system, treated or untreated, whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin
- •12.Abnormal laboratory parameters and vital signs that could increase the risk to the study participant
- •13.Alcohol, drug or medication abuse within the past year
- •14.Severe psychiatric / psychological / neurologic disorders
- •Patients with other known previous / concomitant treatments
- •The following therapy is not allowed within the specified period prior to screening as well as during the study and will prevent the patient from being included into the study:
- •15.SIT against grass pollen within the last 5 years
- •16.7 days prior and 14 days post an immunization with vaccines
- •17.Anti-allergic treatment within the last 4 weeks prior to screening
- •18.b-blocker are not allowed during the entire study and will lead to the patient being withdrawn
- •19.Treatment with substances interfering with the immune system are not allowed during the entire study and will lead to the patient being withdrawn
- •20.Use of other investigational drugs at the time of enrolment or within 30 days
- •21.Treatment with systemic corticosteroids within 3 months prior to the study
- •22.Patients who are expected to be non-compliant and/or not co-operative
- •23.Participation in any other clinical study within the last 30 days prior to the start of the study
- •24.Patients who have already participated in this study
- •25.Patients who are employees at the investigational site, relatives or spouses of the investigator
- •26.Any donation of germ cells, blood, organs, or bone marrow during the course of the study
- •27.Patients who are not contractually capable
- •Special restrictions for female patients
- •28.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation
- •29.Women of child
研究者
相似试验
尚未招募
2 期
Efficacy of Seasonal Influenza Vaccine (SIV) or Flu vaccine” in cancer patients undergoing chemotherapy.Efficacy of flu vaccine in cancer patient undergoing chemotherapyCancer - Any cancerACTRN12611000306910Flinders Medical centre50
进行中（未招募）
不适用
A study to investigate human immune responses in lymph node cells before and after immunisation with a seasonal influenza vaccine in healthy adults with African or Asian ancestryHealthy volunteers receiving a seasonal influenza vaccineISRCTN13657999Imperial College London30
已完成
4 期
The Synergistic Effects of Home-management and Intermittent Preventive Treatment of Malaria in ChildrenMalariaNCT00550160Kwame Nkrumah University of Science and Technology1,490
招募中
不适用
Efficacy of preseasonal treatment on the quality of life in seasonal allergic rhinitisJapanese cedar pollinosisJPRN-UMIN000012877Dept. of Otolaryngology-Head and Neck Surgery Kagoshima University Graduate School of Medical and Dental Sciences200
已完成
不适用
PRE-TREAT: A window study evaluating short term treatment with tamoxifen or letrozole in oestrogen receptive positive breast cancerCancer - BreastBreast cancerACTRN12614000695606Melbourne Health21